Massive study reveals COVID-19's hidden toll on work and wages
NCT ID NCT07072793
First seen Jan 12, 2026 · Last updated May 07, 2026 · Updated 22 times
Summary
This study looked at over 131,000 high-risk people in the US who had mild-to-moderate COVID-19 during the Omicron period. It compared those who took the antiviral Paxlovid with those who didn't, to see how much work they missed and the costs of that lost work. The goal was to understand the economic impact of COVID-19 on people's ability to work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 (CORONAVIRUS DISEASE 2019) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.